Abstract:Gastric cancer is one of the most common cancers and responds poorly to current chemotherapy. Alisertib (ALS) is a second-generation, orally bioavailable, highly selective small-molecule inhibitor of the serine/threonine protein kinase Aurora kinase A (AURKA). ALS has been shown to have potent anticancer effects in preclinical and clinical studies, but its role in gastric cancer treatment is unclear. This study aimed to investigate the cancer cell-killing effect of ALS on gastric cancer cell lines AGS and NCI-N78, with a focus on cell proliferation, cell-cycle distribution, apoptosis, and autophagy and the mechanism of action. The results showed that ALS exhibited potent growth-inhibitory, proapoptotic, and proautophagic effects on AGS and NCI-N78 cells. ALS concentration-dependently inhibited cell proliferation and induced cell-cycle arrest at G2/M phase in both cell lines, with a downregulation of cyclin-dependent kinase 1 and cyclin B1 expression but upregulation of p21 Waf1/Cip1, p27 Kip1, and p53 expression. ALS induced mitochondria-mediated apoptosis and autophagy in both AGS and NCI-N78 cells. ALS induced the expression of proapoptotic proteins but inhibited the expression of antiapoptotic proteins, with a significant increase in the release of cytochrome c and the activation of caspase 9 and caspase 3 in both cell lines. ALS induced inhibition of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and p38 mitogen-activated protein kinase (MAPK) signaling pathways while activating the 5'-adenosine monophosphate-activated protein kinase (AMPK) signaling pathway as indicated by their altered phosphorylation, contributing to the proautophagic effects of ALS. SB202191 and wortmannin enhanced the autophagy-inducing effect of ALS in AGS and NCI-N78 cells. Notably, ALS treatment significantly decreased the ratio of phosphorylated AURKA over AURKA, which may contribute, at least in part, to the inducing effects of ALS on cell-cycle arrest and autophagy in AGS and NCI-N78 cells. Taken together, these results indicate that ALS exerts a potent inhibitory effect on cell proliferation but inducing effects on cell-cycle arrest, mitochondria-dependent apoptosis, and autophagy with the involvement of PI3K/Akt/mTOR, p38 MAPK, and AURKA-mediated signaling pathways in AGS and NCI-N78 cells.

Alisertib Promotes Apoptosis and Autophagy in Melanoma Through P38 MAPK-mediated Aurora a Signaling

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells

Inhibition of Mitotic Aurora Kinase A by Alisertib Induces Apoptosis and Autophagy of Human Gastric Cancer AGS and NCI-N78 Cells.

Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells

Pro-apoptotic and Pro-Autophagic Effects of the Aurora Kinase A Inhibitor Alisertib (MLN8237) on Human Osteosarcoma U-2 OS and MG-63 Cells Through the Activation of Mitochondria-Mediated Pathway and Inhibition of P38 MAPK/PI3K/Akt/mTOR Signaling Pathway

Alisertib Induces Cell Cycle Arrest and Autophagy and Suppresses Epithelial-to-mesenchymal Transition Involving PI3K/Akt/mTOR and Sirtuin 1-Mediated Signaling Pathways in Human Pancreatic Cancer Cells

Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells.

Alisertib, an Aurora Kinase A Inhibitor, Induces Apoptosis and Autophagy but Inhibits Epithelial to Mesenchymal Transition in Human Epithelial Ovarian Cancer Cells

Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells

Alisertib Induces Apoptosis and Autophagy Through Targeting the AKT/mTOR/AMPK/p38 Pathway in Leukemic Cells.

Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression

Modulation of Oxidative Phosphorylation Augments Antineoplastic Activity of Mitotic Aurora Kinase Inhibition

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

Inhibition of AURKB, regulated by pseudogene <i>MTND4P12</i>, confers synthetic lethality to PARP inhibition in skin cutaneous melanoma

A SILAC-based Proteomics Elicits the Molecular Interactome of Alisertib (MLN8237) in Human Erythroleukemia K562 Cells.

Inhibition of MAPK Signaling Pathways Enhances Cell Death Induced by 5-Aminolevulinic Acid-Photodynamic Therapy in Skin Squamous Carcinoma Cells

Aurora A Inhibition Eliminates Myeloid Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in Breast Cancer

Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells

Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma

Augmentation of Danusertib's Anticancer Activity Against Melanoma by Blockage of Autophagy.

Alantolactone Induces Apoptosis Through ROS-mediated AKT Pathway and Inhibition of PINK1-mediated Mitophagy in Human HepG2 Cells.